American Journal of Laboratory Medicine

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Seroprevalence of SARS-CoV-2 IgG Among Medical Care Providers in Sana’a Capital, Yemen, 2021

Medical care providers (MCPs) have a higher risk of contracting infection SARS-CoV-2 during medical care provision to infected patients. This study determined the seroprevalence of SARS-CoV-2 IgG and associated factors among MCPs in Sana’a Capital. A cross-sectional study among MCPs of six of the main Sana'a Capital hospitals was conducted. Data were collected by a self-administered questionnaire that was 288 distributed to MCPs, and blood samples were collected from participants, and tested for SARS-COV-2 IgG antibodies. Data entered and analyzed by Epi info 7.2.4. Univariate logistic regression to determine the association, and calculate crude and adjusted prevalence odds ratio. P-value < 0.05 were considered statistically significant. 288 of MCPs were enrolled, 72% were males, 52% were <30 years old, 65% were married, 84% were nurses, 53% working at ICUs and 58% were from public hospitals. SARS-COV-2 IgG was detected in 242 with 84% overall prevalence among MCPs. It was significantly higher among MCPs at private hospitals than public hospitals and no significant difference according to other sociodemographic factors. IgG seroprevalence of SARS-COV-2 was high. Implementation of effective standards for infection prevention and control (IPC) with sufficient personal protective equipment. Further studies to assess IPC practices and to identify risk factors among MCPs-related SARS-COV-2 infection are required.

SARS-COV-2, IgG Seroprevalence, Medical Care Providers, Yemen

APA Style

Elham Zeehrah, Mohammed Al-Amad. (2023). Seroprevalence of SARS-CoV-2 IgG Among Medical Care Providers in Sana’a Capital, Yemen, 2021. American Journal of Laboratory Medicine, 8(2), 21-26. https://doi.org/10.11648/j.ajlm.20230802.12

ACS Style

Elham Zeehrah; Mohammed Al-Amad. Seroprevalence of SARS-CoV-2 IgG Among Medical Care Providers in Sana’a Capital, Yemen, 2021. Am. J. Lab. Med. 2023, 8(2), 21-26. doi: 10.11648/j.ajlm.20230802.12

AMA Style

Elham Zeehrah, Mohammed Al-Amad. Seroprevalence of SARS-CoV-2 IgG Among Medical Care Providers in Sana’a Capital, Yemen, 2021. Am J Lab Med. 2023;8(2):21-26. doi: 10.11648/j.ajlm.20230802.12

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Sahu AK AV, Mathew R, Aggarwal P, Nayer J, Bhoi S. SARS-COV-2 in health care workers’ e a systematic review and meta-analysis. Am J Emerg Med 2020; 38 (1727e31).
2. Grant JJ, Wilmore SM, McCann NS, Donnelly O, Lai RW, Kinsella MJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. Infection Control & Hospital Epidemiology. 2021; 42 (2): 212-4.
3. Kataria Y, Cole M, Duffy E, de la Cena K, Schechter-Perkins EM, Bouton TC, et al. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts. Scientific reports. 2021; 11 (1): 9694.
4. Zhong B-L, Luo W, Li H-M, Zhang Q-Q, Liu X-G, Li W-T, et al. Knowledge, attitudes, and practices towards SARS-COV-2 among Chinese residents during the rapid rise period of the SARS-COV-2 outbreak: a quick online cross-sectional survey. International journal of biological sciences. 2020; 16 (10): 1745.
5. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England journal of medicine. 2020.
6. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015: 1-23.
7. Rohde R. Novel coronavirus (2019-nCoV) update: uncoating the virus. Am Soc Microbiol. 2020.
8. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020; 579 (7798): 270-3.
9. Velavan TP, Meyer CG. The COVID-19 epidemic. Tropical medicine & international health. 2020; 25 (3): 278.
10. Hopkins J. University of Medicine. Coronavirus Resource Center. SARS-COV-2 Dashboard by the Center for Systems Science and Engineering CSSE at Johns Hopkins Available online at: https://coronavirus jhu edu/map htmlURL. 2020.
11. Meng L, Hua F, Bian Z. Coronavirus disease 2019 (SARS-COV-2): emerging and future challenges for dental and oral medicine. Journal of dental research. 2020; 99 (5): 481-7.
12. Singhal T. A review of coronavirus disease-2019 (SARS-COV-2). The indian journal of pediatrics. 2020; 87 (4): 281-6.
13. World Health Organiaztion. WHO Coronavirus (SARS-COV-2) Dashboard | WHO Coronavirus (SARS-COV-2) Dashboard With Vaccination Data. Accesses 21-10-2022.
14. World Health Organiaztion. http://www.emro.who.int/health-topics/corona-virus/index.html. 2022; Accessed 21-10-2022.
15. Alshaikhli H, Al-Naggar RA, Al-Maktari L, Madram S, Al-Rashidi RR. Epidemiology of SARS-CoV-2 in Yemen: a descriptive study. Int J Life Sci Pharma Res 2020; 10: 134–8.
16. World Health Organiaztion. Yemen: WHO Coronavirus Disease (SARS-COV-2) Dashboard With Vaccination Data | WHO Coronavirus (SARS-COV-2) Dashboard With Vaccination Data. 2022; Accessed 21-10-2022.
17. Al-Naamani K, Al-Jahdhami I, Al-Tamtami W, Al-Amri K, Al-Khabori M, Al Sinani S, et al. Prevalence and Persistence of SARS-CoV2 Antibodies Among Healthcare Workers in Oman. Journal of Infection and Public Health. 2021.
18. Woon YL, Lee YL, Chong YM, Ayub NA, Krishnabahawan SL, Lau JFW, et al. Serology surveillance of SARS-CoV-2 antibodies among healthcare workers in SARS-COV-2 designated facilities in Malaysia. The Lancet Regional Health-Western Pacific. 2021; 9: 100123.
19. Alserehi HA, Alqunaibet AM, Al-Tawfiq JA, Alharbi NK, Alshukairi AN, Alanazi KH, et al. Seroprevalence of SARS-CoV-2 (SARS-COV-2) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagnostic Microbiology and Infectious Disease. 2021; 99 (3): 115273.
20. Al Youha S AO, K. Ibrahim I, Alghounaim M, A. Abu-Sheasha G, Fakhra Z, Al Hendi S, Y AlQabandi, Almazeedi S, Al Asoomi F, Al-Sabah S. Factors associated with SARS-CoV-2 infection amongst healthcare workers in a SARS-COV-2 designated hospital. Journal of Infection and Public Health. 2021 14: 1226–32.
21. Al-Sakkaf E, Ghaleb Y, Al-Dabis E, Qairan M, Al-Amad M, Al-Serouri A, et al. First SARS-COV-2 cases with high secondary infection among health workers, Sana’a capital, April 2020: Lessons learned and future opportunities. International Journal of Infectious Diseases. 2021.
22. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to SARS-COV-2 patients. Journal of Infection. 2020; 81 (3): 420-6.
23. Madsen T, Levin N, Niehus K, Law K, Mayer J, Chapman M, et al. Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees. The American journal of emergency medicine. 2020; 38 (12): 2752.
24. Kasztelewicz B, Janiszewska K, Burzyńska J, Szydłowska E, Migdał M, Dzierżanowska-Fangrat K. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland. Plos one. 2021; 16 (4): e0249550.
25. El-Sokkary RH, Daef E, El-Korashi LA, Khedr EM, Gad D, Mohamed-Hussein A, et al. Sero-prevalence of anti-SARS-CoV-2 antibodies among healthcare workers: A multicenter study from Egypt. Journal of Infection and Public Health. 2021.
26. Barallat J, Fernández-Rivas G, Quirant-Sánchez B, González V, Doladé M, Martinez-Caceres E, et al. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. PLoS One. 2020; 15 (12): e0244348.
27. Zawiah M, Al-Ashwal FY, Saeed RM, Kubas M, Saeed S, Khan AH, et al. Assessment of healthcare system capabilities and preparedness in Yemen to Confront the novel coronavirus 2019 (SARS-COV-2) outbreak: a perspective of healthcare workers. Frontiers in public health. 2020; 8.
28. Schwartz J, King C-C, Yen M-Y. Protecting healthcare workers during the coronavirus disease 2019 (SARS-COV-2) outbreak: lessons from Taiwan’s severe acute respiratory syndrome response. Clinical Infectious Diseases. 2020; 71 (15): 858-60.
29. Verbeek JH, Ijaz S, Mischke C, Ruotsalainen JH, Mäkelä E, Neuvonen K, et al. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. The Cochrane database of systematic reviews. 2016; 4: Cd011621.
30. Chang D, Xu H, Rebaza A, Sharma L, Cruz CSD. Protecting health-care workers from subclinical coronavirus infection. The Lancet Respiratory Medicine. 2020; 8 (3): e13.
31. Wang J, Zhou M, Liu F. Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (SARS-COV-2) in China. J Hosp infect. 2020; 105 (1).
32. Fukuda H, Seyama K, Ito K, Ai T, Nojiri S, Hori S, et al. SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo. Scientific reports. 2021; 11 (1): 1-7.
33. Qiu F, Liang C-L, Liu H, Zeng Y-Q, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? Oncotarget. 2017; 8 (1): 268.
34. Giuca MR, Pasini M, Tecco S, Giuca G, Marzo G. Levels of salivary immunoglobulins and periodontal evaluation in smoking patients. BMC immunology. 2014; 15 (1): 1-5.
35. Pandey KR, Bhattarai A, Pant S, Barakoti R, Pandey J, Subedee A, et al. Seroprevalence of SARS-COV-2 among health workers in the Kathmandu valley, Nepal (SEVID-KaV): a longitudinal cohort study. 2021.
36. Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area. Jama. 2020; 324 (9): 893-5.